Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 04, 2026 07:30 ET | Source: Spur Therapeutics

Spur Therapeutics Presents New Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at 22nd Annual WORLDSymposium™

Spur Therapeutics Presents New Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at 22nd Annual WORLDSymposium
February 02, 2026 01:00 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse : Le venglustat de Sanofi a atteint tous les critères d'évaluation principaux dans une étude de phase 3 sur la maladie de Gaucher de type 3

Le venglustat de Sanofi a atteint tous les critères d'évaluation principaux dans une étude de phase 3 sur la maladie de Gaucher de type 3 Dans l’étude de phase 3 LEAP2MONO, le venglustat, administré...
February 02, 2026 01:00 ET | Source: Sanofi Winthrop Industrie

Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease

Sanofi's investigational drug venglustat improved the neurologic symptoms of type 3 Gaucher disease, for which there are currently no approved therapies.
January 20, 2026 08:01 ET | Source: Spur Therapeutics

Spur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium™

Spur Therapeutics to Present New Clinical Data on Its Gaucher Disease Gene Therapy Candidate at WORLDSymposium
October 07, 2025 02:01 ET | Source: Spur Therapeutics

Spur Therapeutics Presents Updated Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at ESGCT 32nd Annual Congress

Spur Therapeutics Presents Updated Phase 1/2 Durability Data on Its Gene Therapy Candidate in Gaucher Disease at ESGCT 32nd Annual Congress
May 19, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Lysosomal Storage Disorders Market Set to Expand Across the 7MM During the Forecast Period (2025–2034) with Advances in Enzyme Replacement Therapies | DelveInsight

New York, USA, May 19, 2025 (GLOBE NEWSWIRE) -- Lysosomal Storage Disorders Market Set to Expand Across the 7MM During the Forecast Period (2025–2034) with Advances in Enzyme Replacement Therapies |...
October 04, 2023 07:00 ET | Source: Freeline Therapeutics Holdings plc

Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease

Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher
August 15, 2023 07:00 ET | Source: Freeline Therapeutics Holdings plc

Freeline Reports Second Quarter 2023 Financial Results and Business Highlights

Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical data in third quarter of 2023 Extending impact of its novel GCase...
July 25, 2023 07:30 ET | Source: Freeline Therapeutics Holdings plc

Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease

LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced it will host a virtual Key Opinion Leader (KOL) event on FLT201, its adeno-associated...
June 26, 2023 07:30 ET | Source: Freeline Therapeutics Holdings plc

Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease

FLT201 is a highly differentiated AAV gene therapy candidate that delivers a longer-acting engineered variant of GCase, the enzyme missing in people with Gaucher disease Company expects to report...